Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer
16 Maggio 2022 - 2:30PM
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage
precision oncology company designing and developing novel targeted
therapies for cancer treatment, today announced the appointment of
Steve Sabus as Chief Commercial Officer, effective as of May 31,
2022.
Prior to Turning Point, Mr. Sabus spent 15 years in roles with
increasing levels of sales responsibility at Astellas Pharma, most
recently serving as the Head of Oncology leading a group of over
300 team members. In this role he provided executive leadership to
scale the company’s $3 billion U.S. oncology franchise by launching
and growing new products. His achievements include successfully
expanding the market for Xtandi®, directing the ongoing launch of
Padcev®, and developing the commercial strategy for the potential
launch of zolbetuximab, an investigational monoclonal antibody
therapy targeting Claudin18.2.
Earlier in his tenure, Mr. Sabus headed the Astellas $2 billion
U.S. Medical Specialties business unit, and was the General Manager
of Astellas Canada, where the team launched Xospata® and new
indications for Xtandi®.
Before Astellas, Steve spent 16 years at Johnson & Johnson
in roles of increasing responsibility in the commercial
organization.
“I am excited to welcome Steve to the team. His broad commercial
background within oncology across multiple modalities, including
small molecules and ADCs, is highly valuable to us,” said Athena
Countouriotis, M.D., president and CEO. “Steve’s leadership
experience at Astellas demonstrated his keen understanding of the
oncology market and will be instrumental as we grow our internal
team and prepare for the potential commercialization of
repotrectinib.”
“I look forward to joining the Turning Point team at this
important time,” said Mr. Sabus. “I look forward to leveraging my
oncology commercial leadership as we pursue our evolution from a
clinical stage to a commercial stage company. I’m impressed by the
repotrectinib commercial strategy the team has built and my initial
focus will be on preparing the organization for a successful launch
following regulatory approval. I believe repotrectinib represents a
significant opportunity and I am eager to help maximize that
opportunity as this potentially best-in-class compound advances
towards anticipated regulatory approval.”
About Turning Point Therapeutics
Inc.Turning Point Therapeutics is a clinical-stage
precision oncology company with a pipeline of investigational drugs
designed to address key limitations of existing cancer therapies.
The company’s lead drug candidate, repotrectinib, is a
next-generation kinase inhibitor targeting the ROS1 and TRK
oncogenic drivers of non-small cell lung cancer and advanced solid
tumors. Repotrectinib, which is being studied in a registrational
Phase 2 study in adults and a Phase 1/2 study in pediatric
patients, has shown antitumor activity and durable responses among
kinase inhibitor treatment-naïve and pre-treated patients. The
company’s pipeline of drug candidates also includes elzovantinib,
targeting MET, CSF1R and SRC, which is being studied in a Phase 1
trial of patients with advanced or metastatic solid tumors
harboring genetic alterations in MET; TPX-0046, targeting RET,
which is being studied in a Phase 1/2 trial of patients with
advanced or metastatic solid tumors harboring genetic alterations
in RET; TPX-0131, a next-generation ALK inhibitor, which is being
studied in a Phase 1/2 trial of previously treated patients with
ALK-positive advanced or metastatic non-small cell lung cancer; and
TPX-4589 (LM-302), a novel ADC targeting Claudin18.2 which is being
studied in a Phase 1 study in gastrointestinal cancers. The company
is driven to develop therapies that mark a turning point for
patients in their cancer treatment. For more information,
visit www.tptherapeutics.com.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“plans”, “will”, “believes,” “anticipates,” “expects,” “intends,”
“goal,” “potential” and similar expressions are intended to
identify forward-looking statements. Such forward-looking
statements include statements regarding, among other things, the
best-in-class potential of repotrectinib, and plans regarding the
regulatory approval path and commercialization strategy for
repotrectinib. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
forward-looking statements are based upon Turning Point
Therapeutics’ current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Actual results
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with Turning Point Therapeutics’ business
in general, risks and uncertainties related to the impact of the
COVID-19 pandemic to Turning Point Therapeutics’ business and the
other risks described in Turning Point Therapeutics’ filings with
the Securities and Exchange Commission (SEC), including its
quarterly report on Form 10-Q filed with
the SEC on May 10, 2022. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Turning Point
Therapeutics undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Contact: Adam D. Levy, PhD.,
MBAir@tptherapeutics.com858-867-6366
Grafico Azioni Turning Point Therapeutics (NASDAQ:TPTX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Turning Point Therapeutics (NASDAQ:TPTX)
Storico
Da Set 2023 a Set 2024